Literature DB >> 11007538

Inhibition of Ca2+-activated K+ channels by tyrosine phosphatase inhibitors in rat mesenteric artery.

H Yokoshiki1, T Seki, M Sunagawa, N Sperelakis.   

Abstract

To investigate the possible regulation of large-conductance Ca2+-activated K+ channels (BKCa) by tyrosine phosphatases (Tyr-PPs), single-channel currents of myocytes from rat mesenteric artery were recorded in open cell-attached patches. Two structurally different Tyr-PP inhibitors, sodium orthovanadate (Na3VO4) and dephostatin, were used. The channels (236 pS) evoked at +40 mV and pCa 6, were significantly inhibited by 1 mM Na3VO4 (-81+/-3%, n = 10; P < 0.005). Similarly, 100 microM dephostatin strongly inhibited the BKCa channels (-80+/-7%, n = 7 ; P < 0.05). Therefore, BKCa channels in vascular smooth muscle cells may be regulated by tyrosine phosphatase-dependent signal transduction pathways, whose inhibition could attenuate the channel activity.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11007538

Source DB:  PubMed          Journal:  Can J Physiol Pharmacol        ISSN: 0008-4212            Impact factor:   2.273


  3 in total

1.  Multiple actions of halothane on contractile response to noradrenaline in isolated mesenteric resistance arteries.

Authors:  J Yoshino; T Akata; K Izumi; S Takahashi
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2005-07-13       Impact factor: 3.000

2.  Coupling of c-Src to large conductance voltage- and Ca2+-activated K+ channels as a new mechanism of agonist-induced vasoconstriction.

Authors:  Abderrahmane Alioua; Aman Mahajan; Kazuhide Nishimaru; Masoud M Zarei; Enrico Stefani; Ligia Toro
Journal:  Proc Natl Acad Sci U S A       Date:  2002-10-21       Impact factor: 11.205

3.  Tyrphostin AG556 increases the activity of large conductance Ca2+ -activated K+ channels by inhibiting epidermal growth factor receptor tyrosine kinase.

Authors:  Yan Wang; Hai-Ying Sun; Ying-Guang Liu; Zheng Song; Gang She; Guo-Sheng Xiao; Yan Wang; Gui-Rong Li; Xiu-Ling Deng
Journal:  J Cell Mol Med       Date:  2017-03-14       Impact factor: 5.310

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.